| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 37 |
| 1 | CARBOPLATIN | 23 |
| 2 | CAPECITABINE | 20 |
| 3 | DOCETAXEL | 20 |
| 4 | DOCETAXEL ANHYDROUS | 20 |
| 5 | CYCLOPHOSPHAMIDE | 18 |
| 6 | CYCLOPHOSPHAMIDE FOR INJECTION | 18 |
| 7 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 18 |
| 8 | LETROZOLE | 18 |
| 9 | TRASTUZUMAB | 18 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | FLUTAMIDE | 4 | 0.0040 |
| 1 | FEXOFENADINE HYDROCHLORIDE TABLETS | 1 | 0.0039 |
| 2 | LIFILEUCEL | 1 | 0.0035 |
| 3 | PRALATREXATE | 2 | 0.0031 |
| 4 | DEXTROMETHORPHAN HBR, GUAIFENESIN, DOXYLAMINE SUCCINATE | 1 | 0.0023 |
| 5 | EPCORITAMAB-BYSP | 3 | 0.0022 |
| 6 | MOGAMULIZUMAB-KPKC | 3 | 0.0022 |
| 7 | LIDOCAINE HCL 3% | 1 | 0.0022 |
| 8 | TISOTUMAB VEDOTIN | 2 | 0.0021 |
| 9 | SOYBEAN OIL | 1 | 0.0015 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Chemokine Receptor Type 4 Interaction [EPC] | 3 | 0.0022 |
| 1 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 5 | 0.0012 |
| 2 | Endoglycosidase [EPC] | 2 | 0.0011 |
| 3 | Lymphocyte Growth Factor [EPC] | 1 | 0.0008 |
| 4 | Somatostatin Analog [EPC] | 4 | 0.0006 |
| 5 | CD19-directed Chimeric Antigen Receptor [EPC] | 5 | 0.0005 |
| 6 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 4 | 0.0005 |
| 7 | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] | 1 | 0.0004 |
| 8 | Provitamin D2 Compound [EPC] | 13 | 0.0004 |
| 9 | Plasma Kallikrein Inhibitor [EPC] | 1 | 0.0004 |